Tweet
I hope you don't mind, Rebecca, if I post this. I was sent the information by a Harvard ophthalmologist/researcher who suggested I tell everyone on DEZ about these events:
* Experts' Meeting with Regulatory Representatives, entitled "Global Treatments for Dry Eye Syndrome: An Unmet Need." This 5 hour meeting, which will be sponsored by the Tear Film & Ocular Surface Society (TFOS; http://www.TearFilm.org) and the Association for Research in Vision and Ophthalmology (http:// www.arvo.org), will be held in Florence, Italy, on September 22, 2010. The purpose of the Experts' Meeting will be to discuss standard, emerging and accepted clinical endpoints of dry eye syndrome with regulatory authorities and/or experts. We will also consider how to improve clinical trials of treatments for dry eye. The Meeting will be open to basic scientists, clinicians, regulatory officials and industry representatives, and a Meeting report will be published in a peer-reviewed journal. The current program may be found at http://www.tearfilm.org/florence2010...0DRAFT.doc.pdf
* 6th International Conference on the Tear Film & Ocular Surface: Basic Science and Clinical Relevance (http://www.tearfilm.org/florence2010/index.html). This Conference, which will be held in the Palazzo dei Congressi in Florence, Italy, from September 22 to 25, 2010, is designed to: [a] assess the current knowledge and 'state of the art' research on the structure and function of tear film-producing tissues, tears and the ocular surface in both health and disease; [b] promote an international exchange of information that will be of value to basic scientists involved in eye research, to clinicians in the eye care community, and to pharmaceutical companies with an interest in the treatment of tear film or ocular surface disorders. We anticipate over 600 participants from more than 30 countries.
* International Workshop on Meibomian Gland Dysfunction (www.tearfilm.org/mgdworkshop/index.html). Meibomian gland dysfunction (MGD) may well be the leading cause of dry eye syndrome throughout the world. Although this condition impacts the health and well being of millions of people, there is no global consensus on the definition, classification, diagnosis or therapy of MGD. To achieve such a consensus, TFOS, a non-profit organization, launched the International Workshop on Meibomian Gland Dysfunction. The objectives of the MGD Workshop were to: (1) conduct an evidence-based evaluation of meibomian gland structure and function in health and disease; (2) develop a contemporary understanding of the definition and classification of MGD; (3) assess methods of diagnosis, evaluation and grading of severity of MGD; (4) develop appropriate norms of clinical trial design to evaluate pharmaceutical interventions for the treatment of MGD; (5) develop recommendations for the management and therapy of MGD; and (6) create an executive summary of recommendations for future research in MGD. The Workshop, which required more almost 2 years to complete and will finalize its report within the next 2 weeks, involved the efforts of 50 leading clinical and basic research experts from around the world. These individuals were assigned to Subcommittees, reviewed published data and assessed the levels of supporting evidence. Subcommittee reports were circulated, presented in open forum and discussed in an interactive manner. The major report of the TFOS International MGD Workshop will soon be published by ARVO in Investigative Ophthalmology & Visual Science, and will be translated into more than 12 languages.
* Experts' Meeting with Regulatory Representatives, entitled "Global Treatments for Dry Eye Syndrome: An Unmet Need." This 5 hour meeting, which will be sponsored by the Tear Film & Ocular Surface Society (TFOS; http://www.TearFilm.org) and the Association for Research in Vision and Ophthalmology (http:// www.arvo.org), will be held in Florence, Italy, on September 22, 2010. The purpose of the Experts' Meeting will be to discuss standard, emerging and accepted clinical endpoints of dry eye syndrome with regulatory authorities and/or experts. We will also consider how to improve clinical trials of treatments for dry eye. The Meeting will be open to basic scientists, clinicians, regulatory officials and industry representatives, and a Meeting report will be published in a peer-reviewed journal. The current program may be found at http://www.tearfilm.org/florence2010...0DRAFT.doc.pdf
* 6th International Conference on the Tear Film & Ocular Surface: Basic Science and Clinical Relevance (http://www.tearfilm.org/florence2010/index.html). This Conference, which will be held in the Palazzo dei Congressi in Florence, Italy, from September 22 to 25, 2010, is designed to: [a] assess the current knowledge and 'state of the art' research on the structure and function of tear film-producing tissues, tears and the ocular surface in both health and disease; [b] promote an international exchange of information that will be of value to basic scientists involved in eye research, to clinicians in the eye care community, and to pharmaceutical companies with an interest in the treatment of tear film or ocular surface disorders. We anticipate over 600 participants from more than 30 countries.
* International Workshop on Meibomian Gland Dysfunction (www.tearfilm.org/mgdworkshop/index.html). Meibomian gland dysfunction (MGD) may well be the leading cause of dry eye syndrome throughout the world. Although this condition impacts the health and well being of millions of people, there is no global consensus on the definition, classification, diagnosis or therapy of MGD. To achieve such a consensus, TFOS, a non-profit organization, launched the International Workshop on Meibomian Gland Dysfunction. The objectives of the MGD Workshop were to: (1) conduct an evidence-based evaluation of meibomian gland structure and function in health and disease; (2) develop a contemporary understanding of the definition and classification of MGD; (3) assess methods of diagnosis, evaluation and grading of severity of MGD; (4) develop appropriate norms of clinical trial design to evaluate pharmaceutical interventions for the treatment of MGD; (5) develop recommendations for the management and therapy of MGD; and (6) create an executive summary of recommendations for future research in MGD. The Workshop, which required more almost 2 years to complete and will finalize its report within the next 2 weeks, involved the efforts of 50 leading clinical and basic research experts from around the world. These individuals were assigned to Subcommittees, reviewed published data and assessed the levels of supporting evidence. Subcommittee reports were circulated, presented in open forum and discussed in an interactive manner. The major report of the TFOS International MGD Workshop will soon be published by ARVO in Investigative Ophthalmology & Visual Science, and will be translated into more than 12 languages.